AstraZeneca completed the acquisition of Amolyt Pharma from Sofinnova Partners and EQT Life Sciences for $1.05bn.

AstraZeneca, a pharmaceutical company, completed the acquisition of Amolyt Pharma, a global, clinical-stage biopharmaceutical company, from Sofinnova Partners, a European life sciences venture capital firm, and EQT Life Sciences, a healthcare investor, for $1.05bn. "Congratulations to the Amolyt team on its proposed acquisition by AstraZeneca. Leading Amolyt’s Series C financing round in January 2023 was an honor. This milestone demonstrates Sofinnova's investment thesis in action, showcasing our commitment to supporting innovative European companies during their critical growth stage. In Amolyt's case, it exemplifies our commitment to supporting a company developing groundbreaking solutions in a later stage of development for rare disease patients,” Cédric Moreau, Sofinnova Partner.